IDEXX Laboratories, Inc.
IDXX remains a high-quality animal diagnostics franchise, but 41.2x earnings and 10.32x sales already overprice a business guiding to 13%-15% FY26 EPS growth while U.S. clinic traffic is still negative.
IDXX is not expensive because the business is weak. It is expensive because the business is very good, and the market already knows it. The problem is that the stock still asks investors to pay 41.2x earnings and 10.32x sales for a company that grew FY25 revenue 3.9% and is guiding FY26 organic revenue growth of 8.5%-9.7% with 13%-15% comparable EPS growth. That is strong performance, but it is not rare enough to justify paying almost any price.
The core of the bear case is simple. U.S. demand is still soft. Same-store clinical visits were down 1.3% in Q2, and management expects about 1.5% declines in 2H. IDXX is offsetting that softness through price, utilization, international growth, and recurring mix, which speaks well of execution. But when the end market is not fully healthy, the burden on valuation gets heavier, not lighter. This is especially true when the company itself is telling investors that one piece of the business, CAG instrument revenue, was down 20% organic in Q2 because launch timing and comparisons matter.
The second leg of the case is that the quality is already in the stock. Yes, Q2 operating margin reached 35% and FY26 is guided to 32.3%-32.5%, up from 29.2% in FY25. Yes, retention is in the high-90s, premium placements were 5,265 in Q2, and product cadence remains solid with FNA broad availability by year-end and a cancer panel expansion in late Q3. Those facts support a premium multiple. They do not automatically support a multiple this far above peers when the peer average is 35.5x P/E and the quant base target is $449.6.
What keeps conviction at Medium rather than High is management quality. IDXX has beaten EPS in 8 straight quarters, including +8.4% most recently, and it raised guidance despite a $15M FX headwind. The business likely remains a long-term winner. But from $570.58, the next 6 to 12 months look more like a valuation reset than a fresh leg of upside. The stock can be a great company and still be a sell.
New menu launches, inVue Dx ramp, and international expansion sustain double-digit recurring growth and keep investors willing to pay an elite quality multiple.
Execution stays solid and guidance is hit, but valuation compresses toward a more defensible level for a business growing revenue 8.5%-9.7% organic with premium margins.
U.S. visit weakness persists, recurring growth slips below guidance, and the stock derates toward a lower premium multiple as 41.2x P/E proves unsustainable.
Quant call (SELL) diverges from analyst consensus (Buy: 1 buy / 2 hold / 0 sell) — resolve explicitly.
The most dangerous moment comes with victory.
Forward earnings power is improving, with FY26 EPS guided to $14.69-$14.94, but at $570.58 the stock still trades around 38x-39x forward earnings, only modestly below the trailing 41.2x and still above the 35.5x peer average. The moat remains real, anchored by high-90s retention, a large premium installed base, and workflow integration, but over 3-5 years that moat is more likely to widen through software, image interpretation, and assay menu expansion than to justify a permanently extreme multiple. AI is more advantage than threat here because it can deepen diagnostic workflow lock-in, improve interpretation, and raise utilization, but it will not fix the near-term fact pattern of negative U.S. clinic visits and already premium valuation. Regulation looks manageable relative to human diagnostics, so the stock debate is less about existential disruption and more about whether a still-excellent business deserves a 10.32x sales multiple while growth remains high single digit to low double digit.
- FY26 EPS guidance is $14.69-$14.94, implying strong growth, but the stock still trades at roughly 38x-39x forward EPS, above the 35.5x peer average.
- FY26 operating margin guidance of 32.3%-32.5% is materially above FY25's 29.2%, showing real execution and mix benefit, but that improvement is already capitalized in a 10.32x sales multiple.
- U.S. same-store clinical visits were -1.3% in Q2 and management expects about -1.5% in 2H, limiting how far recurring diagnostics can outrun demand softness.
- Q2 revenue rose 10% reported and 9% organic, with 10.3% organic CAG Diagnostics recurring growth, showing the installed base still monetizes well even in a soft visit environment.
- Management raised FY26 revenue guidance to $4.700B-$4.745B and EPS to $14.69-$14.94, with the midpoint up $5M on revenue despite a $15M FX headwind.
- Operating margin was 35% in Q2 and FY26 is guided to 32.3%-32.5%, versus 29.2% in FY25, supported by favorable product costs and a recurring mix shift.
- High-90s customer retention and 5,265 premium placements in Q2, including 1,602 inVue Dx, support durable consumables and software pull-through.
- Valuation is still the problem: 41.2x P/E and 10.32x P/S versus peer averages of 35.5x and 4.7x, while the quant base target is $449.6.
- Demand is not clean: U.S. same-store clinical visits fell 1.3% in Q2, and management said, "At midpoint, we're anticipating second half U.S. clinical visit declines of approximately 1.5%, reflecting similar Q2 trends."
- CAG instrument revenue fell 20% organic as inVue Dx lapped prior broad launch availability, a reminder that hardware growth is less stable than the recurring revenue narrative suggests.
- Free cash flow looked light in FY25 at $0.3B, and shareholder returns are not especially compelling given buybacks of $0.3B against a $43.5B market cap and a Shareholder Returns score of 23.
| Metric | Value | Context |
|---|---|---|
| Current price | $570.58 | Reference point for valuation and scenario analysis |
| Quant price target | $449.6 | -21.2% vs current, Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $4.3B | 3.9% YoY growth |
| FY2025 EPS | $13.17 | 6.6% YoY growth |
| FY2025 operating margin | 29.2% | Up from 29.0% prior year |
| FY2026 revenue guidance | $4.700B-$4.745B | Raised after Q2, 8.5%-9.7% organic growth guide |
| FY2026 EPS guidance | $14.69-$14.94 | Raised after Q2, 13%-15% comparable EPS growth |
| FY2026 operating margin guidance | 32.3%-32.5% | Step-up versus 29.2% in FY2025 |
| Valuation | P/E 41.2 | P/S 10.32 | Above peer averages of 35.5x and 4.7x |
| Leverage | Debt/EBITDA 0.66 | Debt/Equity 0.60 | Balance sheet risk looks manageable |
| Free cash flow | $0.3B | FY2025, with $0.3B buybacks and no dividend |
| 52-week position | -25.9% vs high | -7.7% vs 200-day | Current price below $618.49 200-day average, but still not cheap |
The biggest risk to the bearish view is that IDXX sustains 9.5%-10.7% FY26 CAG Diagnostics recurring organic growth and holds 32.3%-32.5% operating margins, which could keep the premium multiple elevated despite weak clinic visits.
The next catalyst is earnings on November 2, 2026, where investors need to see whether -1.5% expected 2H U.S. clinic visit declines are offset by utilization, international growth, and new product uptake.
Ownership is crowded, with the top 3 institutions holding 72.9% and insiders owning only 0.2%. Short interest is modest at 2.45%, or 1.93M shares, with 3.1 days-to-cover, so there is little fuel for a squeeze. Options positioning is mildly supportive because the zero-gamma level is $556.34, just 2.5% below spot, which can dampen volatility, but that is a trading cushion, not a valuation argument.
9.5%-10.7% FY26 organic growth guide and 10.3% Q2 organic growth make this the core earnings engine.
-20% organic in Q2 as inVue Dx lapped prior launch availability, showing hardware volatility around placement cycles.
Management flagged double-digit international CAG recurring growth, supported by placements, utilization, and commercial expansion in 4 countries.
Mix helped Q2 gross margin, with management citing favorable Water/LPD mix as a contributor to margin expansion.
IDXX posted a strong Q2 and raised FY26 revenue and EPS guidance.
Management has earned credibility on execution. Since the 2024 Q3 call, when IDXX guided to FY24 revenue of $3.865B-$3.890B, EPS of $10.37-$10.53, operating margin of 28.7%-29.0%, and FCF conversion of 90%-95%, the company progressed to FY25 revenue of $4.3B, EPS of $13.17, and 29.2% operating margin, then raised FY26 revenue guidance to $4.700B-$4.745B, EPS to $14.69-$14.94, and operating margin to 32.3%-32.5%. The operational promises around innovation also largely landed: the 2024 Q3 call cited ~700 inVue Dx orders with most deliveries in 2025, and the 2026 Q2 call showed 5,265 premium placements in Q2, including 1,602 inVue Dx, plus FNA broad availability by year-end and cancer panel expansion in late Q3. The one area they have not solved is end-demand, as U.S. same-store clinic visits were -2.1% in 2024 Q3, -1.3% in 2026 Q2, and are expected around -1.5% in 2H, but against that backdrop the company has still delivered 8 straight EPS beats, including +8.4% in the latest quarter.
We're updating our full year revenue range to $4,700 million to $4,745 million, an increase of $5 million at midpoint, net of a $20 million increase in operational performance, offset by a $15 million headwind from updated foreign currency effects.
We're also increasing our full year EPS outlook to $14.69 to $14.94 per share, an increase of $0.14 per share at midpoint, reflecting a 13% to 15% comparable EPS growth range.
During the second quarter, IDEXX delivered excellent financial results, building on strong execution and expansion of IDEXX innovations in our Companion Animal business.
We're seeing a steady ramp internationally as our commercial teams support integration of inVue Dx into practice workflows and awareness builds across regions.
At midpoint, we're anticipating second half U.S. clinical visit declines of approximately 1.5%, reflecting similar Q2 trends. Business momentum combined with recent and upcoming product launches support our outlook for the second half and the full year.
IDXX's moat sits in its veterinary workflow, not just its analyzers. High-90s customer retention, a large premium installed base, consumables pull-through, reference lab integration, and software connectivity make switching costly for clinics that need speed and reliability. The moat still looks durable over the next 3-5 years because menu expansion, image-based diagnostics, and AI-assisted interpretation should deepen usage inside existing accounts, though durability does not mean the stock is immune from valuation compression.
Capital allocation is conservative but not especially shareholder-friendly at this valuation. FY25 showed $0.3B of FCF, $0.3B of buybacks, $0.0B of dividends, and low reported capex in the deep-dive data, while leverage stayed modest at 0.66x debt/EBITDA. That is disciplined, but buybacks at a 41.2x P/E create less value than they would at a lower entry point, so capital deployment does not rescue the current setup.
Rated SELL, Medium conviction. IDXX is a high-quality franchise with real moat characteristics, improving margins, and credible management, but those positives are already more than reflected in a 41.2x P/E and 10.32x P/S. The stock is down 25.9% from its high, yet it still screens expensive against peers and against the engine's $449.6 base value. A change to a more constructive view would require either a materially lower entry price or evidence that growth has stepped up enough to make 38x-39x forward earnings durable despite ongoing U.S. visit declines.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. IDXX rates a SELL at Medium conviction. The company is executing well, raised FY26 guidance, and still compounds through recurring diagnostics, but the stock at $570.58 leaves too little room for a business with U.S. same-store clinical visits down 1.3% and a quant base value of $449.6, or -21.2% from current levels. The setup is better than a broken story, but it is still a bad price.
Investment Thesis
IDXX is not expensive because the business is weak. It is expensive because the business is very good, and the market already knows it. The problem is that the stock still asks investors to pay 41.2x earnings and 10.32x sales for a company that grew FY25 revenue 3.9% and is guiding FY26 organic revenue growth of 8.5%-9.7% with 13%-15% comparable EPS growth. That is strong performance, but it is not rare enough to justify paying almost any price.
The core of the bear case is simple. U.S. demand is still soft. Same-store clinical visits were down 1.3% in Q2, and management expects about 1.5% declines in 2H. IDXX is offsetting that softness through price, utilization, international growth, and recurring mix, which speaks well of execution. But when the end market is not fully healthy, the burden on valuation gets heavier, not lighter. This is especially true when the company itself is telling investors that one piece of the business, CAG instrument revenue, was down 20% organic in Q2 because launch timing and comparisons matter.
The second leg of the case is that the quality is already in the stock. Yes, Q2 operating margin reached 35% and FY26 is guided to 32.3%-32.5%, up from 29.2% in FY25. Yes, retention is in the high-90s, premium placements were 5,265 in Q2, and product cadence remains solid with FNA broad availability by year-end and a cancer panel expansion in late Q3. Those facts support a premium multiple. They do not automatically support a multiple this far above peers when the peer average is 35.5x P/E and the quant base target is $449.6.
What keeps conviction at Medium rather than High is management quality. IDXX has beaten EPS in 8 straight quarters, including +8.4% most recently, and it raised guidance despite a $15M FX headwind. The business likely remains a long-term winner. But from $570.58, the next 6 to 12 months look more like a valuation reset than a fresh leg of upside. The stock can be a great company and still be a sell.
Key Metrics
| Metric | Value | Context | |
|---|---|---|---|
| Current price | $570.58 | Reference point for valuation and scenario analysis | |
| Quant price target | $449.6 | -21.2% vs current, Medium confidence, basis earnings_growth_blend | |
| FY2025 revenue | $4.3B | 3.9% YoY growth | |
| FY2025 EPS | $13.17 | 6.6% YoY growth | |
| FY2025 operating margin | 29.2% | Up from 29.0% prior year | |
| FY2026 revenue guidance | $4.700B-$4.745B | Raised after Q2, 8.5%-9.7% organic growth guide | |
| FY2026 EPS guidance | $14.69-$14.94 | Raised after Q2, 13%-15% comparable EPS growth | |
| FY2026 operating margin guidance | 32.3%-32.5% | Step-up versus 29.2% in FY2025 | |
| Valuation | P/E 41.2 | P/S 10.32 | Above peer averages of 35.5x and 4.7x |
| Leverage | Debt/EBITDA 0.66 | Debt/Equity 0.60 | Balance sheet risk looks manageable |
| Free cash flow | $0.3B | FY2025, with $0.3B buybacks and no dividend | |
| 52-week position | -25.9% vs high | -7.7% vs 200-day | Current price below $618.49 200-day average, but still not cheap |
Financial Strength
Financial quality is good, but not clean enough to justify ignoring price. Leverage is modest at 0.66x debt/EBITDA, profitability is excellent with 22.8% net margin and a path to 32.3%-32.5% operating margin in FY26, and the quality framework supports that with Profitability 97 and Cash Flow Quality 100. The weak spot is cash deployment and balance-sheet flexibility relative to valuation, with Financial Health 43, a 1.17 current ratio, and only $0.3B of FY25 FCF disclosed here. This is a strong business, not a distressed one, but the balance sheet is not so exceptional that investors should shrug off paying well above peer multiples.
Competitive Position
IDXX's moat sits in its veterinary workflow, not just its analyzers. High-90s customer retention, a large premium installed base, consumables pull-through, reference lab integration, and software connectivity make switching costly for clinics that need speed and reliability. The moat still looks durable over the next 3-5 years because menu expansion, image-based diagnostics, and AI-assisted interpretation should deepen usage inside existing accounts, though durability does not mean the stock is immune from valuation compression.
Management & Guidance
Management's current guide is solid and likely achievable. After Q2, the company lifted FY26 revenue to $4.700B-$4.745B and EPS to $14.69-$14.94; as CFO Andrew Emerson said, "We're updating our full year revenue range to $4,700 million to $4,745 million, an increase of $5 million at midpoint, net of a $20 million increase in operational performance, offset by a $15 million headwind from updated foreign currency effects." He also said, "We're also increasing our full year EPS outlook to $14.69 to $14.94 per share, an increase of $0.14 per share at midpoint, reflecting a 13% to 15% comparable EPS growth range." Given 8 consecutive EPS beats, current guide credibility is above average, but the same commentary also admits the key constraint: second half U.S. clinical visit declines of approximately 1.5% are still embedded in the outlook.
Segment Analysis
- Companion Animal Group diagnostics recurring (N/A): 9.5%-10.7% FY26 organic growth guide and 10.3% Q2 organic growth make this the core earnings engine.
- CAG instrument revenue (N/A): -20% organic in Q2 as inVue Dx lapped prior launch availability, showing hardware volatility around placement cycles.
- International CAG (N/A): Management flagged double-digit international CAG recurring growth, supported by placements, utilization, and commercial expansion in 4 countries.
- Water and LPD (N/A): Mix helped Q2 gross margin, with management citing favorable Water/LPD mix as a contributor to margin expansion.
Capital Allocation
Capital allocation is conservative but not especially shareholder-friendly at this valuation. FY25 showed $0.3B of FCF, $0.3B of buybacks, $0.0B of dividends, and low reported capex in the deep-dive data, while leverage stayed modest at 0.66x debt/EBITDA. That is disciplined, but buybacks at a 41.2x P/E create less value than they would at a lower entry point, so capital deployment does not rescue the current setup.
Management Execution & Track Record
Management has earned credibility on execution. Since the 2024 Q3 call, when IDXX guided to FY24 revenue of $3.865B-$3.890B, EPS of $10.37-$10.53, operating margin of 28.7%-29.0%, and FCF conversion of 90%-95%, the company progressed to FY25 revenue of $4.3B, EPS of $13.17, and 29.2% operating margin, then raised FY26 revenue guidance to $4.700B-$4.745B, EPS to $14.69-$14.94, and operating margin to 32.3%-32.5%. The operational promises around innovation also largely landed: the 2024 Q3 call cited ~700 inVue Dx orders with most deliveries in 2025, and the 2026 Q2 call showed 5,265 premium placements in Q2, including 1,602 inVue Dx, plus FNA broad availability by year-end and cancer panel expansion in late Q3. The one area they have not solved is end-demand, as U.S. same-store clinic visits were -2.1% in 2024 Q3, -1.3% in 2026 Q2, and are expected around -1.5% in 2H, but against that backdrop the company has still delivered 8 straight EPS beats, including +8.4% in the latest quarter.
Positioning & Flows
Ownership is crowded, with the top 3 institutions holding 72.9% and insiders owning only 0.2%. Short interest is modest at 2.45%, or 1.93M shares, with 3.1 days-to-cover, so there is little fuel for a squeeze. Options positioning is mildly supportive because the zero-gamma level is $556.34, just 2.5% below spot, which can dampen volatility, but that is a trading cushion, not a valuation argument.
Bull Case
- Q2 revenue rose 10% reported and 9% organic, with 10.3% organic CAG Diagnostics recurring growth, showing the installed base still monetizes well even in a soft visit environment.
- Management raised FY26 revenue guidance to $4.700B-$4.745B and EPS to $14.69-$14.94, with the midpoint up $5M on revenue despite a $15M FX headwind.
- Operating margin was 35% in Q2 and FY26 is guided to 32.3%-32.5%, versus 29.2% in FY25, supported by favorable product costs and a recurring mix shift.
- High-90s customer retention and 5,265 premium placements in Q2, including 1,602 inVue Dx, support durable consumables and software pull-through.
Bear Case
- Valuation is still the problem: 41.2x P/E and 10.32x P/S versus peer averages of 35.5x and 4.7x, while the quant base target is $449.6.
- Demand is not clean: U.S. same-store clinical visits fell 1.3% in Q2, and management said, "At midpoint, we're anticipating second half U.S. clinical visit declines of approximately 1.5%, reflecting similar Q2 trends."
- CAG instrument revenue fell 20% organic as inVue Dx lapped prior broad launch availability, a reminder that hardware growth is less stable than the recurring revenue narrative suggests.
- Free cash flow looked light in FY25 at $0.3B, and shareholder returns are not especially compelling given buybacks of $0.3B against a $43.5B market cap and a Shareholder Returns score of 23.
Valuation & Price Target
Engine price target $449.6 (-21.2% vs current), Medium confidence.
- P/E Multiple: $509.56 (28% weight)
- P/S Multiple: $297.13 (20% weight)
- Quality-adjusted: $593.4 (20% weight)
- DCF: $175.36 (5% weight)
This call aligns with the quant baseline SELL. The base value of $449.6 implies -21.2% downside from $570.58, and that is hard to ignore when the stock trades at 41.2x earnings and 10.32x sales despite FY25 revenue growth of only 3.9% and ongoing negative U.S. clinic visits. The strong part of the story is real, specifically FY26 EPS guidance of $14.69-$14.94, 32.3%-32.5% operating margin guidance, and a long beat streak, which is why conviction is not high and why a more aggressive downside call is unwarranted. Sell-side consensus sits at 1 buy and 2 holds, but with only 3 firms and low signal, it does not offset the valuation gap or the wide peer dispersion of 4.4x in the comp set.
Risk Assessment
Risk score 51/100 (Moderate). The biggest risk to the bearish view is that IDXX sustains 9.5%-10.7% FY26 CAG Diagnostics recurring organic growth and holds 32.3%-32.5% operating margins, which could keep the premium multiple elevated despite weak clinic visits.
The Bottom Line
Rated SELL, Medium conviction. IDXX is a high-quality franchise with real moat characteristics, improving margins, and credible management, but those positives are already more than reflected in a 41.2x P/E and 10.32x P/S. The stock is down 25.9% from its high, yet it still screens expensive against peers and against the engine's $449.6 base value. A change to a more constructive view would require either a materially lower entry price or evidence that growth has stepped up enough to make 38x-39x forward earnings durable despite ongoing U.S. visit declines.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr